Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israeli drug development company BioLineRx has initiated a clinical study to determine the efficacy of its investigational antipsychotic for the treatment of schizophrenia.
Subscribe to our email newsletter
The trial, which is being conducted following the successful filing of an investigational new drug application with the FDA, is designed as a single-center, randomized, open-label, sequential cohort clinical study to be conducted at Uppsala, Sweden.
The results of the study will provide further data related to the anticipated efficacy of the BL-1020 compound – the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial will also supply additional safety, tolerability and pharmacokinetic data.
BioLineRx expects to initiate its phase II maximal tolerated dose clinical trial for BL-1020 in the end of June, 2007.
Morris Laster, CEO of BioLineRx, said: “We are looking forward to the results of this receptor occupancy study that we believe will provide important information regarding the mechanism of action and efficacy of the BL-1020 compound. We believe that BL-1020 holds great potential as a next generation antipsychotic which will be efficacious with minimal therapy-limiting side effects.”